Phio Pharmaceuticals Corp. (PHIO) 10-Year Financial Performance & Capital Metrics

PHIO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Show more

Revenue $0
EBITDA -$7M +30.6%
Net Income -$7M +34.0%
EPS (Diluted) -0.91 +98.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -114.83% +1.5%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-7.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM-294107.81%

ROCE

10Y Avg-109.15%

5Y Avg-93.92%

3Y Avg-101.5%

Latest-118.64%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	34K	19K	15K	138K	21K	0	0	0	0	0
Revenue Growth %	-0.52%	-0.44%	-0.21%	8.2%	-0.85%	-1%	-	-	-	-
Cost of Goods Sold+	6.92M	5.42M	5.37M	4.33M	0	3.72M	8.89M	7.01M	6.33M	3.64M
COGS % of Revenue	203.68%	285%	358%	31.35%	-	-	-	-	-	-
Gross Profit+	-6.89M	-5.4M	-5.36M	-4.19M	21K	-3.72M	-8.89M	-7.01M	-6.33M	-3.64M
Gross Margin %	-202.68%	-284%	-357%	-30.35%	1%	-	-	-	-	-
Gross Profit Growth %	-0.23%	0.22%	0.01%	0.22%	1.01%	-177.95%	-1.39%	0.21%	0.1%	0.42%
Operating Expenses+	10.27M	9.03M	9.38M	7.5M	9.01M	5.08M	4.63M	4.45M	4.49M	3.74M
OpEx % of Revenue	302.09%	475.47%	625.4%	54.36%	428.95%	-	-	-	-	-
Selling, General & Admin	3.35M	3.62M	4.01M	3.18M	4.71M	5.08M	4.63M	4.45M	4.29M	3.74M
SG&A % of Revenue	98.41%	190.47%	267.4%	23.01%	224.19%	-	-	-	-	-
Research & Development	6.92M	5.42M	5.37M	4.33M	4.3M	3.72M	8.89M	7.01M	6.33M	3.64M
R&D % of Revenue	203.68%	285%	358%	31.35%	204.76%	-	-	-	-	-
Other Operating Expenses	2.44M	3.11M	4.7M	4K	0	-3.72M	-8.89M	-7.01M	-6.13M	-3.64M
Operating Income+	-10.24M	-9.02M	-14.06M	-7.36M	-8.99M	-8.79M	-13.51M	-11.46M	-10.82M	-7.39M
Operating Margin %	-301.09%	-474.47%	-937.47%	-53.36%	-427.95%	-	-	-	-	-
Operating Income Growth %	-0.16%	0.12%	-0.56%	0.48%	-0.22%	0.02%	-0.54%	0.15%	0.06%	0.32%
EBITDA+	-10.16M	-8.96M	-13.99M	-7.28M	-8.92M	-8.72M	-13.44M	-11.39M	-10.64M	-7.38M
EBITDA Margin %	-298.82%	-471.68%	-932.8%	-52.78%	-424.76%	-	-	-	-	-
EBITDA Growth %	-0.16%	0.12%	-0.56%	0.48%	-0.22%	0.02%	-0.54%	0.15%	0.07%	0.31%
D&A (Non-Cash Add-back)	77K	53K	70K	81K	67K	72K	75K	71K	184K	2K
EBIT	-10.24M	-9.02M	-14.07M	-7.36M	-8.99M	-8.79M	-13.51M	-11.46M	-10.83M	-7.39M
Net Interest Income+	16K	15K	-1K	0	0	0	0	0	0	231K
Interest Income	16K	15K	0	0	0	0	0	0	0	231K
Interest Expense	0	0	1K	0	0	0	0	0	0	0
Other Income/Expense	14K	21K	-11K	4K	79K	-1K	224K	-18K	-2K	237K
Pretax Income+	-10.22M	-8.99M	-14.07M	-7.36M	-8.91M	-8.79M	-13.29M	-11.48M	-10.83M	-7.15M
Pretax Margin %	-300.68%	-473.37%	-938.2%	-53.33%	-424.19%	-	-	-	-	-
Income Tax+	-91K	-74K	-1.62M	4K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.88%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-10.22M	-8.99M	-12.45M	-7.36M	-8.91M	-8.79M	-13.29M	-11.48M	-10.83M	-7.15M
Net Margin %	-300.68%	-473.37%	-830.13%	-53.33%	-424.19%	-	-	-	-	-
Net Income Growth %	-0.16%	0.12%	-0.38%	0.41%	-0.21%	0.01%	-0.51%	0.14%	0.06%	0.34%
Net Income (Continuing)	-10.22M	-8.99M	-12.45M	-7.36M	-8.91M	-8.79M	-13.29M	-11.48M	-10.83M	-7.15M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-93029.39	-79282.81	-32801.22	-6218.35	-2074.18	-207.25	-111.32	-89.61	-46.76	-0.91
EPS Growth %	0.61%	0.15%	0.59%	0.81%	0.67%	0.9%	0.46%	0.2%	0.48%	0.98%
EPS (Basic)	-93029.39	-79282.81	-32801.22	-6218.35	-2074.18	-207.25	-111.32	-89.61	-46.87	-0.91
Diluted Shares Outstanding	110	113	380	1.18K	4.26K	42.43K	118.68K	126.16K	231.51K	7.87M
Basic Shares Outstanding	110	113	380	1.18K	4.26K	42.43K	118.68K	126.16K	231K	7.87M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.98M	13.11M	3.83M	15.15M	7.3M	15.16M	24.73M	12.45M	9.32M	5.74M
Cash & Short-Term Investments	10.62M	12.91M	3.58M	14.88M	6.93M	14.24M	24.06M	11.78M	8.49M	5.38M
Cash Only	5.12M	12.91M	3.58M	14.88M	6.93M	14.24M	24.06M	11.78M	8.49M	5.38M
Short-Term Investments	5.5M	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	50K	50K	50K	50K	50K	50K	50K	50K	832K	354K
Total Non-Current Assets+	181K	291K	266K	172K	739K	575K	443K	368K	42K	2K
Property, Plant & Equipment	163K	114K	248K	172K	721K	557K	416K	344K	39K	2K
Fixed Asset Turnover	0.21x	0.17x	0.06x	0.80x	0.03x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	154.5K	0	0	0	0	0	0	0	0
Other Non-Current Assets	18K	22.5K	18K	0	18K	18K	27K	24K	3K	0
Total Assets+	11.16M	13.4M	4.1M	15.32M	8.04M	15.74M	25.17M	12.81M	9.36M	5.74M
Asset Turnover	0.00x	0.00x	0.00x	0.01x	0.00x	-	-	-	-	-
Asset Growth %	0.21%	0.2%	-0.69%	2.74%	-0.48%	0.96%	0.6%	-0.49%	-0.27%	-0.39%
Total Current Liabilities+	2.27M	2.54M	2.27M	1.74M	1.88M	2.2M	3.07M	1.94M	1.63M	1.01M
Accounts Payable	1.16M	917K	511K	550K	809K	728K	283K	779K	657K	253K
Days Payables Outstanding	61.3	61.81	34.73	46.41	-	71.51	11.62	40.55	37.87	25.35
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	551K	722K	0	19K	720K	731K
Current Ratio	4.84x	5.16x	1.69x	8.69x	3.88x	6.91x	8.06x	6.42x	5.71x	5.65x
Quick Ratio	4.84x	5.16x	1.69x	8.69x	3.88x	6.91x	8.06x	6.42x	5.71x	5.65x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	411K	526K	170K	35K	0	0
Long-Term Debt	0	0	0	0	0	231K	0	0	0	0
Capital Lease Obligations	0	0	0	0	411K	295K	170K	35K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	2.27M	2.54M	2.27M	1.74M	2.29M	2.72M	3.24M	1.97M	1.63M	1.01M
Total Debt+	0	0	0	0	518K	642K	295K	170K	35K	0
Net Debt	-5.12M	-12.91M	-3.58M	-14.88M	-6.42M	-13.6M	-23.76M	-11.61M	-8.46M	-5.38M
Debt / Equity	-	-	-	-	0.09x	0.05x	0.01x	0.02x	0.00x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-14062.00x	-	-	-	-	-	-	-
Total Equity+	8.89M	10.86M	1.83M	13.58M	5.75M	13.02M	21.93M	10.84M	7.73M	4.72M
Equity Growth %	2.24%	0.22%	-0.83%	6.41%	-0.58%	1.26%	0.68%	-0.51%	-0.29%	-0.39%
Book Value per Share	80899.08	95687.66	4828.51	11471.85	1348.54	306.77	184.79	85.92	33.39	0.60
Total Shareholders' Equity	8.89M	10.86M	1.83M	13.58M	5.75M	13.02M	21.93M	10.84M	7.73M	4.72M
Common Stock	7K	1K	0	2K	1K	1K	0	0	0	0
Retained Earnings	-57.1M	-66.1M	-78.55M	-85.91M	-94.82M	-103.61M	-116.9M	-128.38M	-139.21M	-146.36M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-778K	-831K	-900K	-981K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.32M	-7.76M	-9.51M	-7.52M	-8.64M	-8.8M	-11.86M	-12.13M	-10.75M	-7.11M
Operating CF Margin %	-215.21%	-408.42%	-634.27%	-54.49%	-411.67%	-	-	-	-	-
Operating CF Growth %	0.06%	-0.06%	-0.23%	0.21%	-0.15%	-0.02%	-0.35%	-0.02%	0.11%	0.34%
Net Income	-10.22M	-8.99M	-12.45M	-7.36M	-8.91M	-8.79M	-13.29M	-11.48M	-10.83M	-7.15M
Depreciation & Amortization	77K	53K	70K	81K	67K	72K	75K	193K	184K	35K
Stock-Based Compensation	1.53M	756K	314K	282K	300K	136K	480K	414K	303K	147K
Deferred Taxes	0	0	-1.62M	0	0	0	-233K	0	0	0
Other Non-Cash Items	228K	-9K	4.71M	405K	109K	111K	117K	0	126K	-6K
Working Capital Changes	1.07M	434K	-530K	-523K	-213K	-327K	990K	-1.26M	-536K	-138K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	878K	-246K	-608K	39K	259K	-81K	-445K	496K	-122K	-404K
Cash from Investing+	-5.56M	5.35M	-103K	-5K	-72K	-19K	-51K	-121K	-5K	8K
Capital Expenditures	-57K	-4K	-203K	-5K	-72K	-19K	-51K	-121K	-5K	-1K
CapEx % of Revenue	1.68%	0.21%	13.53%	0.04%	3.43%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-5.5K	-150K	100K	0	0	0	0	0	0	9K
Cash from Financing+	9.49M	10.2M	292K	18.82M	772K	16.13M	21.72M	-26K	7.41M	4M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-209K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	9.7M	0	0	0	69K	3.85M	2.15M	-28K	-26K	-5K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.37M	-7.76M	-9.72M	-7.53M	-8.72M	-8.82M	-11.91M	-12.25M	-10.75M	-7.11M
FCF Margin %	-216.88%	-408.63%	-647.8%	-54.53%	-415.1%	-	-	-	-	-
FCF Growth %	0.06%	-0.05%	-0.25%	0.23%	-0.16%	-0.01%	-0.35%	-0.03%	0.12%	0.34%
FCF per Share	-67103.47	-68440.26	-25596.65	-6357.76	-2045.09	-207.89	-100.34	-97.10	-46.45	-0.90
FCF Conversion (FCF/Net Income)	0.72x	0.86x	0.76x	1.02x	0.97x	1.00x	0.89x	1.06x	0.99x	0.99x
Interest Paid	0	0	0	0	0	0	0	0	11K	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-175.73%	-91.1%	-196.28%	-95.52%	-92.19%	-93.73%	-76.04%	-70.06%	-116.6%	-114.83%
Return on Invested Capital (ROIC)	-203.49%	-785.28%	-	-	-	-	-	-	-	-
Gross Margin	-20267.65%	-28400%	-35700%	-3034.78%	100%	-	-	-	-	-
Net Margin	-30067.65%	-47336.84%	-83013.33%	-5333.33%	-42419.05%	-	-	-	-	-
Debt / Equity	-	-	-	-	0.09x	0.05x	0.01x	0.02x	0.00x	-
Interest Coverage	-	-	-14062.00x	-	-	-	-	-	-	-
FCF Conversion	0.72x	0.86x	0.76x	1.02x	0.97x	1.00x	0.89x	1.06x	0.99x	0.99x
Revenue Growth	-52.11%	-44.12%	-21.05%	820%	-84.78%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Phio Pharmaceuticals Corp. (PHIO) grew revenue by 0.0% over the past year. Growth has been modest.

Phio Pharmaceuticals Corp. (PHIO) reported a net loss of $8.0M for fiscal year 2024.

Dividend & Returns

Phio Pharmaceuticals Corp. (PHIO) has a return on equity (ROE) of -114.8%. Negative ROE indicates the company is unprofitable.

Phio Pharmaceuticals Corp. (PHIO) had negative free cash flow of $7.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Phio Pharmaceuticals Corp. (PHIO) 10-Year Financial Performance & Capital Metrics

PHIO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$7M +30.6%
Net Income -$7M +34.0%
EPS (Diluted) -0.91 +98.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -114.83% +1.5%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-7.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM-294107.81%

ROCE

10Y Avg-109.15%

5Y Avg-93.92%

3Y Avg-101.5%

Latest-118.64%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	34K	19K	15K	138K	21K	0	0	0	0	0
Revenue Growth %	-0.52%	-0.44%	-0.21%	8.2%	-0.85%	-1%	-	-	-	-
Cost of Goods Sold+	6.92M	5.42M	5.37M	4.33M	0	3.72M	8.89M	7.01M	6.33M	3.64M
COGS % of Revenue	203.68%	285%	358%	31.35%	-	-	-	-	-	-
Gross Profit+	-6.89M	-5.4M	-5.36M	-4.19M	21K	-3.72M	-8.89M	-7.01M	-6.33M	-3.64M
Gross Margin %	-202.68%	-284%	-357%	-30.35%	1%	-	-	-	-	-
Gross Profit Growth %	-0.23%	0.22%	0.01%	0.22%	1.01%	-177.95%	-1.39%	0.21%	0.1%	0.42%
Operating Expenses+	10.27M	9.03M	9.38M	7.5M	9.01M	5.08M	4.63M	4.45M	4.49M	3.74M
OpEx % of Revenue	302.09%	475.47%	625.4%	54.36%	428.95%	-	-	-	-	-
Selling, General & Admin	3.35M	3.62M	4.01M	3.18M	4.71M	5.08M	4.63M	4.45M	4.29M	3.74M
SG&A % of Revenue	98.41%	190.47%	267.4%	23.01%	224.19%	-	-	-	-	-
Research & Development	6.92M	5.42M	5.37M	4.33M	4.3M	3.72M	8.89M	7.01M	6.33M	3.64M
R&D % of Revenue	203.68%	285%	358%	31.35%	204.76%	-	-	-	-	-
Other Operating Expenses	2.44M	3.11M	4.7M	4K	0	-3.72M	-8.89M	-7.01M	-6.13M	-3.64M
Operating Income+	-10.24M	-9.02M	-14.06M	-7.36M	-8.99M	-8.79M	-13.51M	-11.46M	-10.82M	-7.39M
Operating Margin %	-301.09%	-474.47%	-937.47%	-53.36%	-427.95%	-	-	-	-	-
Operating Income Growth %	-0.16%	0.12%	-0.56%	0.48%	-0.22%	0.02%	-0.54%	0.15%	0.06%	0.32%
EBITDA+	-10.16M	-8.96M	-13.99M	-7.28M	-8.92M	-8.72M	-13.44M	-11.39M	-10.64M	-7.38M
EBITDA Margin %	-298.82%	-471.68%	-932.8%	-52.78%	-424.76%	-	-	-	-	-
EBITDA Growth %	-0.16%	0.12%	-0.56%	0.48%	-0.22%	0.02%	-0.54%	0.15%	0.07%	0.31%
D&A (Non-Cash Add-back)	77K	53K	70K	81K	67K	72K	75K	71K	184K	2K
EBIT	-10.24M	-9.02M	-14.07M	-7.36M	-8.99M	-8.79M	-13.51M	-11.46M	-10.83M	-7.39M
Net Interest Income+	16K	15K	-1K	0	0	0	0	0	0	231K
Interest Income	16K	15K	0	0	0	0	0	0	0	231K
Interest Expense	0	0	1K	0	0	0	0	0	0	0
Other Income/Expense	14K	21K	-11K	4K	79K	-1K	224K	-18K	-2K	237K
Pretax Income+	-10.22M	-8.99M	-14.07M	-7.36M	-8.91M	-8.79M	-13.29M	-11.48M	-10.83M	-7.15M
Pretax Margin %	-300.68%	-473.37%	-938.2%	-53.33%	-424.19%	-	-	-	-	-
Income Tax+	-91K	-74K	-1.62M	4K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.88%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-10.22M	-8.99M	-12.45M	-7.36M	-8.91M	-8.79M	-13.29M	-11.48M	-10.83M	-7.15M
Net Margin %	-300.68%	-473.37%	-830.13%	-53.33%	-424.19%	-	-	-	-	-
Net Income Growth %	-0.16%	0.12%	-0.38%	0.41%	-0.21%	0.01%	-0.51%	0.14%	0.06%	0.34%
Net Income (Continuing)	-10.22M	-8.99M	-12.45M	-7.36M	-8.91M	-8.79M	-13.29M	-11.48M	-10.83M	-7.15M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-93029.39	-79282.81	-32801.22	-6218.35	-2074.18	-207.25	-111.32	-89.61	-46.76	-0.91
EPS Growth %	0.61%	0.15%	0.59%	0.81%	0.67%	0.9%	0.46%	0.2%	0.48%	0.98%
EPS (Basic)	-93029.39	-79282.81	-32801.22	-6218.35	-2074.18	-207.25	-111.32	-89.61	-46.87	-0.91
Diluted Shares Outstanding	110	113	380	1.18K	4.26K	42.43K	118.68K	126.16K	231.51K	7.87M
Basic Shares Outstanding	110	113	380	1.18K	4.26K	42.43K	118.68K	126.16K	231K	7.87M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.98M	13.11M	3.83M	15.15M	7.3M	15.16M	24.73M	12.45M	9.32M	5.74M
Cash & Short-Term Investments	10.62M	12.91M	3.58M	14.88M	6.93M	14.24M	24.06M	11.78M	8.49M	5.38M
Cash Only	5.12M	12.91M	3.58M	14.88M	6.93M	14.24M	24.06M	11.78M	8.49M	5.38M
Short-Term Investments	5.5M	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	50K	50K	50K	50K	50K	50K	50K	50K	832K	354K
Total Non-Current Assets+	181K	291K	266K	172K	739K	575K	443K	368K	42K	2K
Property, Plant & Equipment	163K	114K	248K	172K	721K	557K	416K	344K	39K	2K
Fixed Asset Turnover	0.21x	0.17x	0.06x	0.80x	0.03x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	154.5K	0	0	0	0	0	0	0	0
Other Non-Current Assets	18K	22.5K	18K	0	18K	18K	27K	24K	3K	0
Total Assets+	11.16M	13.4M	4.1M	15.32M	8.04M	15.74M	25.17M	12.81M	9.36M	5.74M
Asset Turnover	0.00x	0.00x	0.00x	0.01x	0.00x	-	-	-	-	-
Asset Growth %	0.21%	0.2%	-0.69%	2.74%	-0.48%	0.96%	0.6%	-0.49%	-0.27%	-0.39%
Total Current Liabilities+	2.27M	2.54M	2.27M	1.74M	1.88M	2.2M	3.07M	1.94M	1.63M	1.01M
Accounts Payable	1.16M	917K	511K	550K	809K	728K	283K	779K	657K	253K
Days Payables Outstanding	61.3	61.81	34.73	46.41	-	71.51	11.62	40.55	37.87	25.35
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	551K	722K	0	19K	720K	731K
Current Ratio	4.84x	5.16x	1.69x	8.69x	3.88x	6.91x	8.06x	6.42x	5.71x	5.65x
Quick Ratio	4.84x	5.16x	1.69x	8.69x	3.88x	6.91x	8.06x	6.42x	5.71x	5.65x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	411K	526K	170K	35K	0	0
Long-Term Debt	0	0	0	0	0	231K	0	0	0	0
Capital Lease Obligations	0	0	0	0	411K	295K	170K	35K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	2.27M	2.54M	2.27M	1.74M	2.29M	2.72M	3.24M	1.97M	1.63M	1.01M
Total Debt+	0	0	0	0	518K	642K	295K	170K	35K	0
Net Debt	-5.12M	-12.91M	-3.58M	-14.88M	-6.42M	-13.6M	-23.76M	-11.61M	-8.46M	-5.38M
Debt / Equity	-	-	-	-	0.09x	0.05x	0.01x	0.02x	0.00x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-14062.00x	-	-	-	-	-	-	-
Total Equity+	8.89M	10.86M	1.83M	13.58M	5.75M	13.02M	21.93M	10.84M	7.73M	4.72M
Equity Growth %	2.24%	0.22%	-0.83%	6.41%	-0.58%	1.26%	0.68%	-0.51%	-0.29%	-0.39%
Book Value per Share	80899.08	95687.66	4828.51	11471.85	1348.54	306.77	184.79	85.92	33.39	0.60
Total Shareholders' Equity	8.89M	10.86M	1.83M	13.58M	5.75M	13.02M	21.93M	10.84M	7.73M	4.72M
Common Stock	7K	1K	0	2K	1K	1K	0	0	0	0
Retained Earnings	-57.1M	-66.1M	-78.55M	-85.91M	-94.82M	-103.61M	-116.9M	-128.38M	-139.21M	-146.36M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-778K	-831K	-900K	-981K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.32M	-7.76M	-9.51M	-7.52M	-8.64M	-8.8M	-11.86M	-12.13M	-10.75M	-7.11M
Operating CF Margin %	-215.21%	-408.42%	-634.27%	-54.49%	-411.67%	-	-	-	-	-
Operating CF Growth %	0.06%	-0.06%	-0.23%	0.21%	-0.15%	-0.02%	-0.35%	-0.02%	0.11%	0.34%
Net Income	-10.22M	-8.99M	-12.45M	-7.36M	-8.91M	-8.79M	-13.29M	-11.48M	-10.83M	-7.15M
Depreciation & Amortization	77K	53K	70K	81K	67K	72K	75K	193K	184K	35K
Stock-Based Compensation	1.53M	756K	314K	282K	300K	136K	480K	414K	303K	147K
Deferred Taxes	0	0	-1.62M	0	0	0	-233K	0	0	0
Other Non-Cash Items	228K	-9K	4.71M	405K	109K	111K	117K	0	126K	-6K
Working Capital Changes	1.07M	434K	-530K	-523K	-213K	-327K	990K	-1.26M	-536K	-138K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	878K	-246K	-608K	39K	259K	-81K	-445K	496K	-122K	-404K
Cash from Investing+	-5.56M	5.35M	-103K	-5K	-72K	-19K	-51K	-121K	-5K	8K
Capital Expenditures	-57K	-4K	-203K	-5K	-72K	-19K	-51K	-121K	-5K	-1K
CapEx % of Revenue	1.68%	0.21%	13.53%	0.04%	3.43%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-5.5K	-150K	100K	0	0	0	0	0	0	9K
Cash from Financing+	9.49M	10.2M	292K	18.82M	772K	16.13M	21.72M	-26K	7.41M	4M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-209K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	9.7M	0	0	0	69K	3.85M	2.15M	-28K	-26K	-5K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.37M	-7.76M	-9.72M	-7.53M	-8.72M	-8.82M	-11.91M	-12.25M	-10.75M	-7.11M
FCF Margin %	-216.88%	-408.63%	-647.8%	-54.53%	-415.1%	-	-	-	-	-
FCF Growth %	0.06%	-0.05%	-0.25%	0.23%	-0.16%	-0.01%	-0.35%	-0.03%	0.12%	0.34%
FCF per Share	-67103.47	-68440.26	-25596.65	-6357.76	-2045.09	-207.89	-100.34	-97.10	-46.45	-0.90
FCF Conversion (FCF/Net Income)	0.72x	0.86x	0.76x	1.02x	0.97x	1.00x	0.89x	1.06x	0.99x	0.99x
Interest Paid	0	0	0	0	0	0	0	0	11K	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-175.73%	-91.1%	-196.28%	-95.52%	-92.19%	-93.73%	-76.04%	-70.06%	-116.6%	-114.83%
Return on Invested Capital (ROIC)	-203.49%	-785.28%	-	-	-	-	-	-	-	-
Gross Margin	-20267.65%	-28400%	-35700%	-3034.78%	100%	-	-	-	-	-
Net Margin	-30067.65%	-47336.84%	-83013.33%	-5333.33%	-42419.05%	-	-	-	-	-
Debt / Equity	-	-	-	-	0.09x	0.05x	0.01x	0.02x	0.00x	-
Interest Coverage	-	-	-14062.00x	-	-	-	-	-	-	-
FCF Conversion	0.72x	0.86x	0.76x	1.02x	0.97x	1.00x	0.89x	1.06x	0.99x	0.99x
Revenue Growth	-52.11%	-44.12%	-21.05%	820%	-84.78%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Phio Pharmaceuticals Corp. (PHIO) grew revenue by 0.0% over the past year. Growth has been modest.

Phio Pharmaceuticals Corp. (PHIO) reported a net loss of $8.0M for fiscal year 2024.

Dividend & Returns

Phio Pharmaceuticals Corp. (PHIO) has a return on equity (ROE) of -114.8%. Negative ROE indicates the company is unprofitable.

Phio Pharmaceuticals Corp. (PHIO) had negative free cash flow of $7.3M in fiscal year 2024, likely due to heavy capital investments.